ABSTRACT. We examined the distribution of major allelic variants of CYP2C9 and CYP2C19 in the Mongolian population of China and compared it with that of other populations. The polymorphisms of CYP2C9 (including the CYP2C9*1, CYP2C9*2 and CYP2C9*3 alleles) and CYP2C19 (including the CYP2C19*1, CYP2C19*2 and CYP2C19*3 alleles) were analyzed in 280 healthy unrelated Chinese Mongolian subjects, using a PCR-RFLP assay. The frequencies of CYP2C9*1, *2 and *3 alleles were 0.97, 0.00 and 0.03, respectively. The frequencies of CYP2C19*1, *2 and *3 alleles were 0.72, 0.24 and 0.04, respectively. We did not find any differences in the allelic distribution of these two genes between age groups. However, the genotype frequency of CYP2C9 *1/*3 was significantly higher in males than in females. Compared with other populations, we found that the allele frequencies of the CYP2C9*2 and CYP2C9*3 allelic variants in this Mongolian population of China were similar to those reported 
INTRODUCTION
More and more studies have revealed that interethnic differences in drug response play an important role in pharmacogenetics. The existence of large population difference with small intra-patient variability is consistent with inheritance as determinant of drug response. It is estimated that genetics can account for 20-95% of variability in drug disposition and effects (Hitchen, 2006) . The cytochrome P450 (CYP450 genes) family enzyme system is a primary metabolic pathway for the metabolism of drugs (Gardiner and Begg, 2006) . CYP450 genes are highly polymorphic, and mutation in different genes can result in altered, reduced, increased, or no enzyme activity or changes in the amount of enzymes (Zhou et al., 2009a) .
CYP2C9 catalyses the oxidation of clinically important drugs including phenytoin, tolbutamide, warfarin, and a large number of nonsteroidal anti-inflammatory drugs (Miners and Birkett, 1998; Zhou et al., 2009b; Kesavan et al., 2010) . Presently, 34 different CYP2C9 allelic variants have been identified (http://www.cypalleles.ki.se/cyp2c9.htm, January 2009). However, CYP2C9*2 (Arg 144 to Cys, rs1799853) and CYP2C9*3 (Ile 359 to Leu, rs1057910) are recognized as main CYP2C9 variants in humans (Lee et al., 2002) . CYP2C9*2 and CYP2C9*3 have reduced catalytic activity compared with the wild-type CYP2C9*1 (Miners and Birkett, 1998; Goldstein, 2001) .
Cytochrome P450 2C19 (CYP2C19) plays an important role in the metabolism of a wide range of therapeutic drugs including barbiturates, diazepam, lansoprazole, mephenytoin, omeprazole, proguanil, and propranolol (Goldstein, 2001; Desta et al., 2002) . Several polymorphisms of CYP2C19 have been identified that produce an inactive enzyme (http://www.cypalleles.ki.se/cyp2c19.htm, June 2009). Two variant alleles account for the majority of the poor metabolizer phenotypes. The first is CYP2C19*2, which carries a G>A nucleotide substitution in exon 5 resulting in an aberrant splice site (rs4244285; de Morais et al., 1994a) . The second variant, CYP2C19*3, which carries a G>A nucleotide substitution at position 636 in exon 4, produces a premature stop codon (rs4986893; de Morais et al., 1994b) .
China has 55 different minorities, accounting for approximately 100 million people. The different genetic backgrounds and diverse environments of the minor populations distinguish them from the Han majority. The Mongolian population represents one of the 15 largest ethnic minorities in China. It consists of 4.2 million people living mainly in the Inner Mongolian province in the northeastern region of China. Pharmacogenetic studies of the functional significance of polymorphisms in the CYP450 genes and their roles as risk factors in drug-induced toxicities and therapeutic failures have been performed in some Chinese populations (Leung et al., 2001; Zhang et al., 2002; Liou et al., 2006) . However, no data have been reported regarding the polymorphism of CYP450 genes in the Mongolian population of China. The aim of this study was thus to investigate the al-lele frequencies of CYP2C9 (*2 and *3) and CYP2C19 (*2 and *3) in a sufficiently large sample of the Mongolian population in China (280 subjects) and to compare our results with the data observed in other ethnic populations.
MATERIAL AND METHODS

Subjects
Inner Mongolia, on the northern frontier of China, stretches all the way from Eastern to Western China. In this study, we estimated the distribution of common variants of CYP2C9 and CYP2C19 in a sample of 280 unrelated healthy Mongolian volunteers (119 males and 161 females aged between 18 and 51 years; with a mean age of 33.0 ± 9.0 years) from Xilinguole Meng located in northeastern Inner Mongolia. They are still nomadic people living on the relatively limited grazing land, thus, they rarely communicate or interact with other cultural groups in Inner Mongolia of China. They have their own ancient language and their own unique cultural traits. All subjects were informed both verbally and in writing about the procedures and purpose of the study. Written informed consents were obtained from all of them. All subjects were healthy and had no abnormalities, as shown by routine histories and physical examinations. The subjects were carefully interviewed and were considered to belong to the Mongolian nationality, by lineage and birth. For all investigated subjects, at least three generations of their family members are from the same nationality. This clinical protocol was approved by the Institution Review Board of Human Medical University and is in compliance with Department of Health and Human Services (DHHS) regulations for protection of human research subjects.
DNA extraction and PCR-RFLP
Three milliliters venous blood was obtained in Vacutainer tubes containing ethylene diamine tetraacetic acid (EDTA), from each subject. Genomic DNA was extracted from peripheral blood leukocytes using a DNA extraction kit from Promega (Germany). The extracted DNA was dissolved in sterile distilled water and stored at -20°C until polymerase chain reaction (PCR) analysis. The amplification procedure was performed in a PCR system gradient master cycler. PCR was performed in a 25-μL reaction mixture containing 2X Taq PCR buffer, 0.4 mM dNTPs, 20 μM of each specific forward and reverse primer, 1.25 U Taq DNA polymerase, and 500 ng template DNA. The amplification program was as follows: 1) initial denaturation at 94°C for 5 min, 2) 35 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 30 s, extension at 72°C for 45 s, and 3) final extension at 72°C for 10 min. The amplification primers were the same as previously described (Kimura et al., 1987; Niu et al., 2004) . The PCR products of CYP2C9*2, CYP2C9*3, CYP2C19*2, and CYP2C19*3 were digested with AvaII, NsiI, SmaI, and BamHI, respectively. Digested PCR products were analyzed by 3% agarose gels stained with ethidium bromide and then visualized and documented.
Statistical analysis
Allele distributions were compared using c 2 and Fisher exact tests. P < 0.05 was con-Distribution of CYP450 in Chinese Mongolians sidered to be significant. These analyses were performed by SPSS (SPSS Inc., Chicago, USA, for Windows, version 11.000).
RESULTS
The allele and genotype frequencies of CYP2C9 and CYP2C19 in the Chinese Mongolians are summarized in Tables 1 and 2 . For CYP2C9, 97% of the studied subjects were found to be the wild type. The CYP2C9*2 allele was not detected in this study and the allele frequency for CYP2C9*3 was 0.03. The allele frequencies of CYP2C19*1, *2, and *3 were 0.72, 0.24, and 0.04, respectively. Of the 22 poor metabolizers of CYP2C19, 18 were found to be homozygous of the CYP2C19*2 variant, 2 were homozygous of the CYP2C19*3 variant, and 2 were heterozygous of both variants.
Table1. Allele frequencies of CYP2C9 and CYP2C19 in the Mongolian population.
Gene
Variant allele Frequency (N = 560, %)
0.04% N = number of alleles.
Further analysis showed that the low-activity allele of CYP2C9*3 (slow metabolizer) was significantly more common in men than in women (P < 0.005); no other gender difference was detected for the two genes in the studied population (Table 2) . No significant difference was detected in different age groups for the allele and genotype frequencies of these two genes ( Table 2) .
The allele frequencies of these two genes in the Mongolian population were compared with those in the other populations (Table 3) . In contrast to the significantly lower frequency of the CYP2C9*2 allele in the Mongolians than that in the African-American and American populations, the frequency of the CYP2C9*3 allele in the Mongolians was significantly higher than that in both populations. Allelic distributions of CYP2C9*2 and CYP2C9*3 were similar among Mongolian, Han Chinese, and Japanese populations. For the gene CYP2C19, the allele frequency of CYP2C19*2 was significantly higher than that in Caucasians, but was similar to that in Africans and other Asians. The allele frequency of the CYP2C19*3 was significantly higher than that in African-American and American populations. No significant difference of CYP2C19*3 frequency was found among the Asian groups.
DISCUSSION
In our study, CYP2C9*2 was absent in the Chinese Mongolian population, which was consistent with the previous reports in Orientals (Sullivan-Klose et al., 1996; Xie et al., 2002) . These findings confirmed that the CYP2C9*2 allele mutation occurred rarely in the East Asian populations, which is in contrast with the higher frequency of the CYP2C9*2 variant among Caucasians. The CYP2C9*2 allele occurs at a significantly lower frequency in the AfricanAmerican population compared to Caucasians. In the case of CYP2C9*3, the allele frequency in the Chinese Mongolian population was similar to that in Han Chinese and Japanese, but was higher than that in Caucasians and Africans. In our study, we identified 7% of the subjects with the CYP2C9*1/*3 heterozygote, but no subjects with the CYP2C9*3/*3 homozygote were detected. This result is similar to that in other Eastern populations (Xie et al., 2002) . However, our results showed that 90% of the CYP2C9*1/*3 genotype in the Chinese Mongolian were from men (P < 0.005). Considering the relatively small sample size, this finding should be further confirmed with a larger sample size. The CYP2C9*2 or CYC2P9*3 variant has been associated with an increased risk of serious or life threatening bleeding events in warfarintreated patients (Sanderson et al., 2005; Goto et al., 2010) . Therefore, identifying CYP2C9 variants could potentially improve clinical management in patients commencing warfarin, especially for male patients in the Chinese Mongolian population, if our finding is confirmed in the future.
The genetic polymorphism of CYP2C19 has been shown to have the most striking interethnic variation of all the CYPs so far. Both CYP2C19*2 and CYP2C19*3 alleles were reported to produce truncated proteins without enzyme activity (Gardiner and Begg, 2006) . The allele frequency of CYP2C19*2 in our study was in agreement with previous studies in Han Chinese (Chen et al., 2008) , Japanese and African populations (Goldstein et al., 1997) , but was significantly higher than that observed in Caucasians (Goldstein et al., 1997) . Our result showed that the frequency of CYP2C19*3 was slightly lower than that in other Asian populations such as Taiwanese, Japanese or Korean (Roh et al., 1996; Goldstein et al., 1997; Liou et al., 2006) ; however, it was significantly higher than that in Caucasians and Africans (Goldstein et al., 1997) . The CYP2C19*1/*2 and CYP2C19*1/*3, which indicate the intermediate metabolizer classification, accounted for about 41% (95% confidence interval: 0.35 ± 0.064) of CYP2C19 genotypes in the Mongolian population, which was similar to that in Mainland Han Chinese (Chen et al., 2008) , but lower than that in Han Taiwanese (Liou et al., 2006) . The frequency (8.0%) of poor metabolizer including CYP2C19*2/*2, CYP2C19*2/*3 and CYP2C19*3/*3 altogether in Chinese Mongolians was similar to other Asian populations but markedly higher than in Caucasians and Africans (2 to 7%; Bertilsson, 1995) . These data suggest that different ethnic groups may exhibit different sensitivities to drugs metabolized by CYP2C19.
The individual response to a drug, such as the risk of toxicity, is a complex equation involving multiple variables. However, genetic polymorphisms (usually inactivating) are one N = total number of alleles; **P < 0.05 compared to the Mongolian population; ***P < 0.001 compared to the Mongolian population.
of the major causes of variation in drug responsiveness (Evans and Johnson, 2001) . It has been reported that the drug doses used in clinical trials with East Asian participants are lower than those used in trials with Western participants (Yu et al., 1996; Ross et al., 2001) . Understanding the genotype and frequency of CYP450 allelic variations in the Chinese Mongolian population may help in the development of appropriate strategies for drug therapy, clinical safety, and to improve public health care in this community.
CONCLUSION
In summary, our study showed that the CYP2C9 and CYP2C19 variants in Chinese Mongolians are similar to other Asian populations but significantly different from Caucasians and African-Americans. Considering the similarity in allele distribution between Chinese Mongolians and other Asian populations, it may be expected that the severity of drug side effects or lack of efficacy due to individual genetic backgrounds in Chinese Mongolians are also similar to that of other Asian groups.
